Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
Burger
Maximilian
M
D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D003408:Cresols / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053202:Urinary Incontinence, Urge / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate